Identification of an AluY-mediated deletion of exon 5 in the CPOX gene by MLPA analysis in patients with hereditary coproporphyria

被引:9
作者
Barbaro, M. [1 ,3 ]
Kotajarvi, M. [1 ,2 ]
Harper, P. [1 ,2 ,4 ]
Floderus, Y. [1 ,2 ,4 ]
机构
[1] Karolinska Univ Hosp, Ctr Inherited Metab Dis, SE-14180 Stockholm, Sweden
[2] Karolinska Univ Hosp, Porphyria Ctr Sweden, SE-14180 Stockholm, Sweden
[3] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden
[4] Karolinska Inst, Dept Lab Med, Div Metab Dis, Stockholm, Sweden
关键词
AluY-mediated deletion; coproporphyrinogen oxidase; CPOX; HCP; hereditary coproporphyria; MLPA; SYNTHETIC PROBE SET; ACUTE PORPHYRIAS; OXIDASE ACTIVITY; MUTATIONS; ASSAY;
D O I
10.1111/j.1399-0004.2011.01628.x
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Hereditary coproporphyria (HCP) is an autosomal dominantly inherited hepatic porphyria, caused by a mutation in the coproporphyrinogen oxidase (CPOX) gene. The genetic defect leads to a partial defect of CPOX, the sixth enzyme involved in haem biosynthesis. Affected individuals can develop acute life- threatening attacks of neurovisceral symptoms and/ or more rarely cutaneous symptoms such as skin fragility and blistering. The identification of the genetic defect in HCP families is of crucial importance to detect the carrier status which allows counselling to prevent possible triggering factors, e. g. certain drugs, alcohol, or fasting. In a total of nine Swedish HCP families, routine gene sequence analysis had identified a causative mutation in only five. In the present study, using an in- house developed synthetic probe set for multiplex ligation- dependent probe amplification (MLPA) analysis, we detected a deletion of the fifth exon in the CPOX gene in the remaining four families. The deletion is 3381 bp in size and has originated by an Alu- mediated mechanism. This finding emphasizes the usefulness of MLPA analysis as a complement to gene sequencing for comprehensive genetic diagnostics in HCP patients.
引用
收藏
页码:249 / 256
页数:8
相关论文
共 20 条
[1]   Hepatocellular carcinoma in patients with acute hepatic porphyria:: frequency of occurrence and related factors [J].
Andant, C ;
Puy, H ;
Bogard, C ;
Faivre, J ;
Soulé, JC ;
Nordmann, Y ;
Deybach, JC .
JOURNAL OF HEPATOLOGY, 2000, 32 (06) :933-939
[2]  
[Anonymous], The Drug Database for Acute Porphyria website
[3]   Gene dosage imbalances in patients with 46,XY gonadal DSD detected by an in-house-designed synthetic probe set for multiplex ligation-dependent probe amplification analysis [J].
Barbaro, M. ;
Cicognani, A. ;
Balsamo, A. ;
Lofgren, A. ;
Baldazzi, L. ;
Wedell, A. ;
Oscarson, M. .
CLINICAL GENETICS, 2008, 73 (05) :453-464
[4]   Front line tests for the investigation of suspected porphyria [J].
Deacon, AC ;
Elder, GH .
JOURNAL OF CLINICAL PATHOLOGY, 2001, 54 (07) :500-507
[5]  
den Dunnen JT, 2000, HUM MUTAT, V15, P7
[6]  
Gu Wenli, 2008, Pathogenetics, V1, P4, DOI 10.1186/1755-8417-1-4
[7]   ACCURATE AND SPECIFIC HPLC ASSAY OF COPROPORPHYRINOGEN-III OXIDASE ACTIVITY IN HUMAN PERIPHERAL LEUKOCYTES [J].
GUO, R ;
LIM, CK ;
PETERS, TJ .
CLINICA CHIMICA ACTA, 1988, 177 (03) :245-252
[8]   Characterization of mutations in the CPO gene in British patients demonstrates absence of genotype-phenotype correlation and identifies relationship between hereditary coproporphyria and harderoporphyria [J].
Lamoril, J ;
Puy, H ;
Whatley, SD ;
Martin, C ;
Woolf, JR ;
Da Silva, V ;
Deybach, JC ;
Elder, GH .
AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (05) :1130-1138
[9]   A HIGH-PERFORMANCE-LIQUID-CHROMATOGRAPHIC METHOD FOR THE ASSAY OF COPROPORPHYRINOGEN OXIDASE ACTIVITY IN RAT-LIVER [J].
LI, F ;
LIM, CK ;
PETERS, TJ .
BIOCHEMICAL JOURNAL, 1986, 239 (02) :481-484
[10]   Hereditary coproporphyria [J].
Martásek, P .
SEMINARS IN LIVER DISEASE, 1998, 18 (01) :25-32